(19)
(11) EP 4 739 313 A1

(12)

(43) Date of publication:
13.05.2026 Bulletin 2026/20

(21) Application number: 24751584.4

(22) Date of filing: 03.07.2024
(51) International Patent Classification (IPC): 
A61K 31/4709(2006.01)
A61K 31/706(2006.01)
A61P 35/02(2006.01)
 A61K 31/635(2006.01)
A61K 45/06(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/4709; A61K 31/635; A61K 31/706; A61P 35/02; A61K 45/06
 
C-Sets:
  1. A61K 31/4709, A61K 2300/00;
  2. A61K 31/635, A61K 2300/00;
  3. A61K 31/706, A61K 2300/00;
(86) International application number:
PCT/US2024/036827
(87) International publication number:
WO 2025/014784 (16.01.2025 Gazette 2025/03)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 07.07.2023 US 202363525639 P

(71) Applicant: Rigel Pharmaceuticals, Inc.
South San Francisco, CA 94080 (US)

(72) Inventors:
  • CHAO, Mwe Mwe
    San Francisco, California 94080 (US)
  • DINARDO, Courtney
    San Francisco, California 94080 (US)

(74) Representative: J A Kemp LLP 
80 Turnmill Street
London EC1M 5QU
London EC1M 5QU (GB)

   


(54) TREATMENT OF ACUTE MYELOID LEUKEMIA WITH OLUTASIDENIB, VENETOCLAX AND A HYPOMETHYLATING AGENT